MX2021014892A - Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide. - Google Patents

Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide.

Info

Publication number
MX2021014892A
MX2021014892A MX2021014892A MX2021014892A MX2021014892A MX 2021014892 A MX2021014892 A MX 2021014892A MX 2021014892 A MX2021014892 A MX 2021014892A MX 2021014892 A MX2021014892 A MX 2021014892A MX 2021014892 A MX2021014892 A MX 2021014892A
Authority
MX
Mexico
Prior art keywords
rheumatoid arthritis
compositions
methods
treating pain
subj ects
Prior art date
Application number
MX2021014892A
Other languages
English (en)
Inventor
Stefano Fiore
Toshio Kimura
Susan Boklage
John Gregory St
Wenhui Wei
Vivian Bykerk
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Publication of MX2021014892A publication Critical patent/MX2021014892A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación se refiere al uso de un anticuerpo anti-receptor de IL6 para tratar un dolor inaceptable en sujetos con artritis reumatoide. Los sujetos con dolor inaceptable pueden tener, p. ej., dolor refractario o dolor refractario estricto.
MX2021014892A 2019-06-04 2020-06-03 Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide. MX2021014892A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962857247P 2019-06-04 2019-06-04
US201962930966P 2019-11-05 2019-11-05
EP20305191 2020-02-27
PCT/US2020/035871 WO2020247461A1 (en) 2019-06-04 2020-06-03 Compositions and methods for treating pain in subj ects with rheumatoid arthritis

Publications (1)

Publication Number Publication Date
MX2021014892A true MX2021014892A (es) 2022-06-27

Family

ID=71842803

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014892A MX2021014892A (es) 2019-06-04 2020-06-03 Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide.

Country Status (14)

Country Link
US (1) US20200399380A1 (es)
EP (1) EP3980459A1 (es)
JP (1) JP2022534794A (es)
KR (1) KR20230061198A (es)
CN (1) CN115667301A (es)
AU (1) AU2020288561A1 (es)
BR (1) BR112021024445A2 (es)
CA (1) CA3142710A1 (es)
CO (1) CO2021017737A2 (es)
IL (1) IL288573A (es)
MA (1) MA56116A (es)
MX (1) MX2021014892A (es)
TW (1) TW202110892A (es)
WO (1) WO2020247461A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024526414A (ja) * 2022-04-06 2024-07-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-6rアンタゴニストを投与することによってリウマチ性多発筋痛症を処置するための組成物および方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
EP1912284B1 (en) 2005-07-29 2012-04-11 Fujitsu Ltd. Rf tag and rf tag manufacturing method
CN102585002A (zh) 2006-06-02 2012-07-18 瑞泽恩制药公司 人il-6受体的高亲和力抗体
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
ES2894259T3 (es) * 2014-09-16 2022-02-14 Sanofi Biotechnology Composiciones para mejorar la calidad de vida relacionada con la salud de pacientes con artritis reumatoide

Also Published As

Publication number Publication date
BR112021024445A2 (pt) 2022-02-15
CN115667301A (zh) 2023-01-31
TW202110892A (zh) 2021-03-16
CO2021017737A2 (es) 2022-05-20
AU2020288561A1 (en) 2021-12-23
IL288573A (en) 2022-02-01
JP2022534794A (ja) 2022-08-03
MA56116A (fr) 2022-04-13
CA3142710A1 (en) 2020-12-10
EP3980459A1 (en) 2022-04-13
WO2020247461A1 (en) 2020-12-10
US20200399380A1 (en) 2020-12-24
KR20230061198A (ko) 2023-05-08

Similar Documents

Publication Publication Date Title
PH12020551932A1 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
ZA201903327B (en) Compositions and methods for the induction of cd8+ t¿cells
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
PH12021550152A1 (en) Anti-cd112r compositions and methods
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
TN2019000289A1 (en) Treatment of asthma with anti-tslp antibody
PH12020551671A1 (en) Chimeric receptors to dll3 and methods of use thereof
MX2021002180A (es) Composiciones de inhibidores del receptor de quimiocina c-x-c tipo 4 (cxcr4) y metodos de preparacion y uso.
MX2020000342A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos.
SG10201804000TA (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
MY187975A (en) Antigen-binding proteins that activate the leptin receptor
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
MX2023014841A (es) Composiciones para tratar artritis reumatoide.
MX2022001008A (es) Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores.
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
IL282375A (en) For the delay and treatment of synucleopathy, tauopathy and other diseases 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
WO2017136834A8 (en) Methods of differentiating stem cell-derived ectodermal lineage precursors
MX2018001849A (es) Metodos y composiciones que usan bifidobacterium longum para modular la reactividad emocional y tratar o prevenir perturbaciones subclinicas del estado de animo.
IL280824A (en) Methods and compositions for the treatment of rheumatoid arthritis patients
MX2021014892A (es) Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide.
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
MX2022015030A (es) Composiciones y metodos para el tratamiento del dolor no inflamatorio en sujetos con artritis reumatoide.
MX2021001877A (es) Composiciones y métodos para el tratamiento de lesión pulmonar aguda.